Glycobiology Advance Access published online on July 25, 2006
Glycobiology, doi:10.1093/glycob/cwl028
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Endocrinology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
* To whom correspondence should be addressed. Galectin-8 and galectin-9, which each consist of two carbohydrate recognition domains joined by a linker peptide, belong to the tandem-repeat-type subclass of the galectin family. Alternative splicing leads to the formation of at least two and three distinct splice variants (isoforms) of galectin-8 and galectin-9, respectively, with tandem-repeat-type structures. The isoforms share identical carbohydrate recognition domains and differ only in the linker region. In a search for differences in biological activity among the isoforms, we found that their isoforms with the longest linker peptide, i.e., galectin-8L and galectin-9L, are highly susceptible to thrombin cleavage. While the predominant isoforms, galectin-8M and galectin-9M, and other members of human galectin family so far examined were resistant to thrombin. Amino acid sequence analysis of proteolytic fragments and site-directed mutagenesis showed that the thrombin cleavage sites (-IAPRT- and -PRPRG- for galectin-8L and galectin-9L, respectively) resided within the linker peptides. Although intact galectin-8L stimulated neutrophil adhesion to substrate more efficiently than galectin-8M, the activity of galectin-8L but not that of galectin-8M decreased on thrombin digestion. Similarly, thrombin treatment almost completely abolished eosinophil chemoattractant activity of galectin-9L. These observations suggest that galectin-8L and galectin-9L play unique roles in relation to coagulation and inflammation.
Received June 5, 2006
Revised July 19, 2006
Accepted July 23, 2006
Communication
Galectin-8 and galectin-9 are novel substrates for thrombin
Nozomu Nishi 1 *, Aiko Itoh 2, Hiroki Shoji 1, Hiroshi Miyanaka 3, and Takanori Nakamura 1
2 GalPharma Co., Ltd., 2217-44 Hayashimachi, Takamatsu, Kagawa 761-0301, Japan
3 Life Science Research Center, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
Nozomu Nishi, E-mail: nnishi{at}med.kagawa-u.ac.jp
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. Klibi, T. Niki, A. Riedel, C. Pioche-Durieu, S. Souquere, E. Rubinstein, S. Le Moulec, J. Guigay, M. Hirashima, F. Guemira, et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells Blood, February 26, 2009; 113(9): 1957 - 1966. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Stowell, C. M. Arthur, K. A. Slanina, J. R. Horton, D. F. Smith, and R. D. Cummings Dimeric Galectin-8 Induces Phosphatidylserine Exposure in Leukocytes through Polylactosamine Recognition by the C-terminal Domain J. Biol. Chem., July 18, 2008; 283(29): 20547 - 20559. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamamoto, N. Nishi, H. Shoji, A. Itoh, L.-H. Lu, M. Hirashima, and T. Nakamura Induction of Cell Adhesion by Galectin-8 and its Target Molecules in Jurkat T-Cells J. Biochem., March 1, 2008; 143(3): 311 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Carlsson, C. T Oberg, M. C Carlsson, A. Sundin, U. J Nilsson, D. Smith, R. D Cummings, J. Almkvist, A. Karlsson, and H. Leffler Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface Glycobiology, June 1, 2007; 17(6): 663 - 676. [Abstract] [Full Text] [PDF] |
||||



